Obesity In India

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

India still has a critical advantage: ultra-processed foods account for a very small share of current diets

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Why does belly fat creep up after 30 even if nothing has changed? A California-based gastroenterologist trained at AIIMS explains the science behind it and what can help reverse it

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Mounjaro is part of a new generation of weight-loss and diabetes drugs that target metabolic hormones. Introduced in March, it was launched ahead of rival Novo Nordisk's Wegovy

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

The development comes in line with growing obesity numbers in India, with a recent Lancet study projecting over 440 million obese and overweight people by 2050

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

A new Aiims study reveals a worrying rise in obesity, hypertension and hidden metabolic risks among Delhi schoolchildren, especially those in private schools

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

India's per capita oil intake has jumped to 23.5 kg a year-nearly twice the ICMR's limit-raising health concerns over obesity, heart disease, and diabetes